Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study have?
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study has 3 citations in the OpenAlex counts ScholarIQ stores.
When was Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study published?
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study has 2022 year in the ScholarIQ index.
What is the open-access status of Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study?
Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study has gold oa status in the ScholarIQ index.
What is the DOI of Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study?
The DOI for Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study is on the source record.
What is the PMID of Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study?
The PMID for Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study is on the source record.
What is the OpenAlex record for Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study?
The OpenAlex for Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study is on the source record.